• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一组针对患有饮食失调合并抑郁症和焦虑症的住院患者进行基于氯胺酮辅助心理治疗的病例系列。

A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders.

作者信息

Robison Reid, Lafrance Adele, Brendle Madeline, Smith Michelle, Moore Claire, Ahuja Sachin, Richards Scott, Hawkins Nicole, Strahan Erin

机构信息

Center for Change, Orem, UT, USA.

Novamind Inc., Draper, UT, USA.

出版信息

J Eat Disord. 2022 May 6;10(1):65. doi: 10.1186/s40337-022-00588-9.

DOI:10.1186/s40337-022-00588-9
PMID:35524316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9077943/
Abstract

BACKGROUND

Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (ED) treatment were assessed.

CASE PRESENTATION

This study reports on five participants with a diagnosis of an ED and comorbid mood and anxiety disorders who received weekly intramuscular ketamine injections in a group setting over 4 weeks. Measures of anxiety (GAD-7) and depression (PHQ-9) were administered pre-dose, 4-h post-dose, and 24-h post dose. Four of the 5 participants experienced clinically significant improvements on the PHQ-9 score (i.e., change greater than 5) while 2 of the 5 participants experienced clinically significant improvements on the GAD-7 score (i.e., change greater than 4) from pre-dose to 24-h post-dose after the last ketamine session. Dosing sessions were well tolerated, and no serious adverse events were reported. Clinical observations and participant reports corroborated improvements in depression and anxiety symptoms, good tolerability of ketamine treatment, and practical implementation of the G-KAP protocol in a residential ED treatment center.

CONCLUSIONS

This study suggests the potential utility of G-KAP as an adjunct to intensive, specialized ED treatment. Overall, this novel, cross-diagnostic intervention warrants future research to further explore its appropriateness in a treatment setting.

摘要

背景

评估了在强化住院饮食失调(ED)治疗中为患者提供的基于小组的氯胺酮辅助心理治疗(G-KAP)的抑郁和焦虑结果指标、安全性/耐受性、患者满意度以及实施的简易程度。

病例介绍

本研究报告了5名被诊断为患有ED且伴有共病情绪和焦虑障碍的参与者,他们在4周内每周在小组环境中接受一次氯胺酮肌肉注射。在给药前、给药后4小时和给药后24小时进行焦虑(GAD-7)和抑郁(PHQ-9)测量。5名参与者中有4名在最后一次氯胺酮治疗后,从给药前到给药后24小时,PHQ-9评分有临床显著改善(即变化大于5),而5名参与者中有2名在GAD-7评分上有临床显著改善(即变化大于4)。给药过程耐受性良好,未报告严重不良事件。临床观察和参与者报告证实了抑郁和焦虑症状的改善、氯胺酮治疗的良好耐受性以及G-KAP方案在住院ED治疗中心的实际实施情况。

结论

本研究表明G-KAP作为强化、专门的ED治疗辅助手段的潜在效用。总体而言,这种新颖的跨诊断干预值得未来进行研究,以进一步探索其在治疗环境中的适用性。

相似文献

1
A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders.一组针对患有饮食失调合并抑郁症和焦虑症的住院患者进行基于氯胺酮辅助心理治疗的病例系列。
J Eat Disord. 2022 May 6;10(1):65. doi: 10.1186/s40337-022-00588-9.
2
Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants.氯胺酮辅助团体心理治疗用于 COVID-19 相关倦怠和 PTSD 的一线医护人员:10 名参与者的有效性/安全性病例系列。
J Psychoactive Drugs. 2024 Jan-Mar;56(1):23-32. doi: 10.1080/02791072.2023.2186285. Epub 2023 Mar 2.
3
Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review.接受氯胺酮辅助心理治疗的部分有物质使用问题的门诊患者焦虑和抑郁症状减轻:一项为期两年的回顾性病历审查。
Front Psychiatry. 2023 Aug 30;14:1160442. doi: 10.3389/fpsyt.2023.1160442. eCollection 2023.
4
Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses.氯胺酮辅助心理治疗用于患有多种精神疾病诊断的青少年。
Front Psychiatry. 2023 Mar 30;14:1141988. doi: 10.3389/fpsyt.2023.1141988. eCollection 2023.
5
Implementation of transdiagnostic treatment for emotional disorders in residential eating disorder programs: A preliminary pre-post evaluation.在住院饮食失调症项目中实施情绪障碍的跨诊断治疗:初步的前后评估。
Psychother Res. 2019 Nov;29(8):1045-1061. doi: 10.1080/10503307.2018.1446563. Epub 2018 Mar 19.
6
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa.病例报告:肌肉注射氯胺酮或鼻内给予艾司氯胺酮治疗4例伴有神经性厌食症的重度抑郁症患者。
Front Psychiatry. 2023 May 15;14:1181447. doi: 10.3389/fpsyt.2023.1181447. eCollection 2023.
7
A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression.一项基于队列的病例报告:氯胺酮辅助治疗嵌入创伤后应激障碍和抑郁症医疗服务提供者实践社区框架的影响。
Front Psychiatry. 2022 Jan 12;12:803279. doi: 10.3389/fpsyt.2021.803279. eCollection 2021.
8
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review.在“茁壮成长”氯胺酮辅助治疗项目中,肌内注射和舌下含服氯胺酮用于精神疾病治疗的安全性和耐受性:一项回顾性病历审查
Ther Adv Psychopharmacol. 2023 May 25;13:20451253231171512. doi: 10.1177/20451253231171512. eCollection 2023.
9
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.家庭环境下,舌下含服氯胺酮远程医疗对于中重度焦虑和抑郁是一种安全有效的治疗方法:一项大型前瞻性开放标签有效性试验的结果。
J Affect Disord. 2022 Oct 1;314:59-67. doi: 10.1016/j.jad.2022.07.004. Epub 2022 Jul 6.
10
Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.在治疗抵抗的广泛性焦虑和社交焦虑障碍患者中维持氯胺酮治疗的安全性和疗效。
J Psychopharmacol. 2018 Jun;32(6):663-667. doi: 10.1177/0269881118762073. Epub 2018 Mar 21.

引用本文的文献

1
Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.裸盖菇素治疗饮食失调:文献及注册临床试验的系统评价
Eat Weight Disord. 2025 Jul 29;30(1):58. doi: 10.1007/s40519-025-01771-y.
2
Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating.实践社区中的氯胺酮辅助治疗:一种治疗饮食失调的新方法。
Ther Adv Psychopharmacol. 2025 Jul 14;15:20451253251356980. doi: 10.1177/20451253251356980. eCollection 2025.
3
Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.

本文引用的文献

1
Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy.病例报告:极端且持久的神经性贪食症经反复氯胺酮辅助心理治疗后意外缓解
Front Psychiatry. 2021 Nov 17;12:764112. doi: 10.3389/fpsyt.2021.764112. eCollection 2021.
2
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review.氯胺酮治疗神经性厌食症:叙事性综述。
Nutrients. 2021 Nov 20;13(11):4158. doi: 10.3390/nu13114158.
3
Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.
通过解离重新建立联系:一项关于氯胺酮辅助心理治疗神经性厌食症的5个月随访案例研究。
J Eat Disord. 2025 Jun 10;13(1):107. doi: 10.1186/s40337-025-01313-y.
4
Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.氯胺酮作为饮食失调的辅助治疗:一项病例系列探索性研究及回顾性分析。
J Eat Disord. 2025 Mar 17;13(1):48. doi: 10.1186/s40337-025-01232-y.
5
Beyond the numbers: reimagining healing with psychedelics for eating disorders.数字之外:重新构想用迷幻药治疗饮食失调症
J Eat Disord. 2024 Sep 30;12(1):148. doi: 10.1186/s40337-024-01111-y.
6
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.接受氯胺酮治疗精神疾病的人对这种干预措施的主观体验如何?一项定性研究的元综合分析。
Int J Ment Health Nurs. 2025 Feb;34(1):e13425. doi: 10.1111/inm.13425. Epub 2024 Sep 16.
7
Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine : a case report.使用心理治疗辅助静脉注射氯胺酮改善重度及持续性神经性厌食症合并重度抑郁症患者的抑郁症状:一例报告
J Eat Disord. 2024 Jun 12;12(1):79. doi: 10.1186/s40337-024-01039-3.
8
Established and emerging treatments for eating disorders.已确立和新兴的进食障碍治疗方法。
Trends Mol Med. 2024 Apr;30(4):392-402. doi: 10.1016/j.molmed.2024.02.009. Epub 2024 Mar 18.
9
Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors.在果蝇中微剂量使用氯胺酮不会阻断5-羟色胺再摄取,但会引起由谷氨酸和5-羟色胺受体介导的复杂行为变化。
J Neurochem. 2024 Jun;168(6):1097-1112. doi: 10.1111/jnc.16070. Epub 2024 Feb 7.
10
Microdosing ketamine in does not inhibit SERT like SSRIs, but causes behavioral changes mediated by glutamate and serotonin receptors.小剂量氯胺酮不会像选择性5-羟色胺再摄取抑制剂(SSRIs)那样抑制5-羟色胺转运蛋白(SERT),而是会引起由谷氨酸和血清素受体介导的行为变化。
bioRxiv. 2023 Nov 8:2023.11.07.566121. doi: 10.1101/2023.11.07.566121.
氯胺酮和艾司氯胺酮在强迫症(OCD)、物质使用障碍(SUD)和饮食失调(ED)中的治疗潜力:当前文献综述
Brain Sci. 2021 Jun 27;11(7):856. doi: 10.3390/brainsci11070856.
4
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression.一项关于肌肉注射氯胺酮治疗严重且持久的饮食失调症合并难治性抑郁症患者的纵向病例系列研究。
Clin Case Rep. 2021 Apr 4;9(5):e03869. doi: 10.1002/ccr3.3869. eCollection 2021 May.
5
Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review.氯胺酮治疗单相抑郁的有效性和安全性:系统评价。
Psychiatr Q. 2020 Dec;91(4):1147-1192. doi: 10.1007/s11126-020-09830-6.
6
Remission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report.采用生酮饮食和氯胺酮治疗慢性神经性厌食症缓解:病例报告
Front Psychiatry. 2020 Jul 30;11:763. doi: 10.3389/fpsyt.2020.00763. eCollection 2020.
7
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study.缓释氯胺酮片治疗难治性抑郁和焦虑患者的安全性与有效性:开放标签试验研究
Ther Adv Psychopharmacol. 2020 May 18;10:2045125320922474. doi: 10.1177/2045125320922474. eCollection 2020.
8
Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7).7 项广泛性焦虑障碍问卷(GAD-7)的变化敏感性和最小临床重要差异。
J Affect Disord. 2020 Mar 15;265:395-401. doi: 10.1016/j.jad.2020.01.032. Epub 2020 Jan 15.
9
Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.短期氯胺酮治疗治疗抵抗性抑郁症:关注心血管安全性。
Psychiatr Danub. 2019 Sep;31(Suppl 3):585-590.
10
Toward specific ways to combine ketamine and psychotherapy in treating depression.探讨将氯胺酮与心理疗法相结合治疗抑郁症的具体方法。
CNS Spectr. 2020 Jun;25(3):445-447. doi: 10.1017/S1092852919001007. Epub 2019 Jun 19.